Epigenetic code during mycobacterial infections : therapeutic implications for tuberculosis

© 2021 Federation of European Biochemical Societies..

Epigenetics involves changing the gene function without any change in the sequence of the genes. In the case of tuberculosis (TB) infections, the bacilli, Mycobacterium tuberculosis (M.tb), uses epigenetics as a tool to protect itself from the host immune system. TB is a deadly disease-causing maximum death per year due to a single infectious agent. In the case of TB, there is an urgent need for novel host-directed therapies which can effectively target the survival and long-term persistence of the bacteria without developing drug resistance in the bacterial strains while also reducing the duration and toxicity associated with the mainstream anti-TB drugs. Recent studies have suggested that TB infection has a significant effect on the host epigenome thereby manipulating the host immune response in the favor of the pathogen. M.tb alters the activation status of key genes involved in the immune response against TB to promote its survival and subvert the antibacterial strategies of the host. These changes are reversible and can be exploited to design very efficient host-directed therapies to fight against TB. This review has been written with the purpose of discussing the role of epigenetic changes in TB pathogenesis and the therapeutic approaches involving epigenetics, which can be utilized for targeting the pathogen.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:289

Enthalten in:

The FEBS journal - 289(2022), 14 vom: 28. Juli, Seite 4172-4191

Sprache:

Englisch

Beteiligte Personen:

Fatima, Samreen [VerfasserIn]
Kumari, Anjna [VerfasserIn]
Agarwal, Meetu [VerfasserIn]
Pahuja, Isha [VerfasserIn]
Yadav, Vinod [VerfasserIn]
Dwivedi, Ved Prakash [VerfasserIn]
Bhaskar, Ashima [VerfasserIn]

Links:

Volltext

Themen:

Antitubercular Agents
Drug-resistant tuberculosis
Epigenetics
Immunotherapy
Journal Article
Mycobacterium tuberculosis
Research Support, Non-U.S. Gov't
Review
Vaccine

Anmerkungen:

Date Completed 20.07.2022

Date Revised 25.10.2022

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1111/febs.16170

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM329966839